Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany

Journal of Clinical Psychopharmacology

Volumn 32, Issue 5, 2012, Pages 602-607

  Stargardt, Tom ^a   Edel, Marc Andreas ^a,b   Ebert, Andreas ^b   Busse, Reinhard ^c   Juckel, Georg ^b   Gericke, Christian A ^d  

^a UNIVERSITY OF HAMBURG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

^d UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

atypical antipsychotic treatment; cost and effectiveness; Germany; schizophrenia; typical antipsychotic treatment

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BENPERIDOL; BROMPERIDOL; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; FLUSPIRILENE; HALOPERIDOL; LEVOMEPROMAZINE; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PERAZINE; PERPHENAZINE; PIMOZIDE; PIPAMPERONE; PROMAZINE; PROMETHAZINE; PROTHIPENDYL; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; AGED; AGITATION; ANXIETY; ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; GERMANY; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GERMANY; HEALTH CARE COSTS; HUMANS; LENGTH OF STAY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT READMISSION; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84865865530     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318268ddc0     Document Type: Article

References (21)

1. Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.
2. Bromet EJ, Fennig S. Epidemiology and natural history of schizophrenia. Biol Psychiatry. 1999;46(7):871-881.
3. World Health Organization. World Health Report 2003. Geneva, Switzerland: WHO; 2003.
4. Zhang PL, Santos JM, Newcomer J, et al. Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients. Schizophr Res. 2004;71(1):137-144.
5. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346(1):16-22.
6. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet. 2008;371(9618): 1085-1097.
7. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA. 2003;290(20):2693-2702.
8. Sernyak MJ, Leslie D, Rosenheck R. Use of system-wide outcomes monitoring data to compare the effectiveness of atypical neuroleptic medications. Am J Psychiatry. 2003;160(2):310-315.
9. Stargardt T, Weinbrenner S, Busse R, et al. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. J Ment Health Policy Econ. 2008;11(2):89-97.
10. Weiden PJ, Ralphs A, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry. 1996;57(S11): 53-60.
11. Buckley PF, Miller BJ, Lehrer DS, et al. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009;35(2):383-402.
12. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
13. Geddes J, Freemantle N, Harrision P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321(7273):1271-1376.
14. Leucht S, Arbter D, Engel RR, et al. Howeffective are second-generation antipsychotic drugs? a meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14(4):429-447.
15. Leucht S, Corvers C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
16. Davis J, Chen N, Glick I. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6): 553-564.
17. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21(3):419-429.
18. Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv. 2003;54(4):508-516.
19. Tiihonen J,Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalization due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333(7561):224.
20. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152-163.
21. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163(12):2080-2089.